Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells
Abstract Targeted therapy remains the future of anti‐cancer drug development, owing to the lack of specificity of current treatments which lead to damage in healthy normal tissues. ATR inhibitors have in recent times demonstrated promising clinical potential, and are currently being evaluated in the...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2024-09-01
|
| Seri Bilgileri: | Advanced Science |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/advs.202403831 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|